Announcements Trials

Browse Landscape

Phase

Phase 1 25 Phase 2 24 Phase 1/2 18 Phase NA 1 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 40 Dermatologic 26 Genitourinary 23 Gastrointestinal 22 Head & Neck 10 CNS 6 Other solid neoplasm 5 Lymphoid 3 Gynecologic 2 Tumor-Agnostic 1 Sarcoma 1 Plasma cell 1 Breast 1

Conditions

Neoplasms 1 Breast Neoplasms 1

Interventions

Cyclophosphamide 171 Docetaxel 163 Paclitaxel 160 Trastuzumab 151 Capecitabine 130 Tamoxifen 119 Letrozole 105 Epirubicin 93 Doxorubicin 83 Anastrozole 83 exemestane 77 Fulvestrant 75 Carboplatin 64 Fluorouracil 63 Radiotherapy 61 pertuzumab 59 Gemcitabine 55 Vinorelbine 43 Goserelin 39 eribulin 36 130-nm albumin-bound paclitaxel 36 palbociclib 32 Bevacizumab 32 ribociclib 30 Zoledronic Acid 29 Lapatinib 29 Methotrexate 28 Drug Therapy 28 Chemotherapy, Adjuvant 28 Ado-Trastuzumab Emtansine 24

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Nivolumab × Breast × Clear all

NCT04109066 2025-01-08

CheckMate 7FL

Bristol-Myers Squibb

Phase 3 Completed

521 enrolled 17 charts

Breast Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡